A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles

Nanomedicine

Volumn 11, Issue 2, 2016, Pages 107-119

  Lin, Zhoumeng ^a   Monteiro Riviere, Nancy A ^a   Kannan, Raghuraman ^b   Riviere, Jim E ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b University of Missouri   (United States)

Author keywords

Biodistribution; Computational nanotoxicology; Endocytosis; Nanomaterials; Pbpk modeling; Phagocytosis; Physiologically based pharmacokinetic modeling; Toxicokinetics

Indexed keywords

GOLD; NANOPARTICLE;

ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; HUMAN; METABOLIC CLEARANCE RATE; MOUSE; PIG; PROCEDURES; RAT; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; TOXICITY TESTING;

ANIMALS; CELL SURVIVAL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL EXPOSURE; GOLD; HUMANS; METABOLIC CLEARANCE RATE; MICE; MODELS, BIOLOGICAL; NANOPARTICLES; RATS; SPECIES SPECIFICITY; SWINE; TISSUE DISTRIBUTION; TOXICITY TESTS;

EID: 84988452190     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.177     Document Type: Article

References (52)

1. Yamashita K, Yoshioka Y, Higashisaka K et al. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nat. Nanotechnol. 6(5), 321-328 (2011).
2. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem. Soc. Rev. 40(3), 1647-1671 (2011).
3. Oberdörster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1(1), 2-25 (2007).
4. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science 311(5761), 622-627 (2006).
5. Lin Z, Monteiro-Riviere NA, Riviere JE. Pharmacokinetics of metallic nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7(2), 189-217 (2015).
6. Dykman LA, Khlebtsov NG. Uptake of engineered gold nanoparticles into mammalian cells. Chem. Rev. 114(2), 1258-1288 (2014).
7. Landsiedel R, Fabian E, Ma-Hock L et al. Toxico-/biokinetics of nanomaterials. Arch. Toxicol. 86(7), 1021-1060 (2012).
8. Godwin H, Nameth C, Avery D et al. Nanomaterial categorization for assessing risk potential to facilitate regulatory decision-making. ACS Nano 9(4), 3409-3417 (2015).
9. Sahneh FD, Scoglio CM, Monteiro-Riviere NA, Riviere JE. Predicting the impact of biocorona formation kinetics on interspecies extrapolations of nanoparticle biodistribution modeling. Nanomedicine (Lond.) 10(1), 25-33 (2015). Describes the impact of biocorona formation kinetics on the pharmacokinetics of nanomaterials across species.
10. Riviere JE. Of mice, men and nanoparticle biocoronas: are in vitro to in vivo correlations and interspecies extrapolations realistic? Nanomedicine (Lond.) 8(9), 1357-1359 (2013).
11. Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 4(11), 6303-6317 (2010). The first review article on the applications of physiologically based pharmacokinetic modeling in nanomaterial pharmacokinetics and toxicology studies.
12. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol. Sci. 95(2), 300-312 (2007). Develops and applies the principles of nanomaterial dosimetry in vitro and outlines an approach for simulating nanoparticle particokinetics in cell culture systems.
13. Xia XR, Monteiro-Riviere NA, Riviere JE. An index for characterization of nanomaterials in biological systems. Nat. Nanotechnol. 5(9), 671-675 (2010).
14. Meng H, Xia T, George S, Nel AE. A predictive toxicological paradigm for the safety assessment of nanomaterials. ACS Nano 3(7), 1620-1627 (2009). Proposes a predictive toxicological approach for the assessment of nanomaterial hazards.
15. Cohen JM, Teeguarden JG, Demokritou P. An integrated approach for the in vitro dosimetry of engineered nanomaterials. Part. Fibre Toxicol. 11, 20 (2014).
16. Liu R, Rallo R, Weissleder R, Tassa C, Shaw S, Cohen Y. Nano-SAR development for bioactivity of nanoparticles with considerations of decision boundaries. Small 9(9-10), 1842-1852 (2013).
17. Puzyn T, Rasulev B, Gajewicz A et al. Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles. Nat. Nanotechnol. 6(3), 175-178 (2011).
18. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MN. Computational modeling in nanomedicine: prediction of multiple antibacterial profiles of nanoparticles using a quantitative structure-activity relationship perturbation model. Nanomedicine (Lond.) 10(2), 193-204 (2015).
19. Kleandrova VV, Luan F, Gonzalez-Diaz H, Ruso JM, Speck-Planche A, Cordeiro MN. Computational tool for risk assessment of nanomaterials: novel QSTR-perturbation model for simultaneous prediction of ecotoxicity and cytotoxicity of uncoated and coated nanoparticles under multiple experimental conditions. Environ. Sci. Technol. 48(24), 14686-14694 (2014).
20. Lee HA, Leavens TL, Mason SE, Monteiro-Riviere NA, Riviere JE. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. Nano Lett. 9(2), 794-799 (2009).
21. Li D, Johanson G, Emond C, Carlander U, Philbert M, Jolliet O. Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats. Nanotoxicology 8, 128-137 (2014).
22. Bachler G, Von Goetz N, Hungerbuhler K. Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO) nanoparticles. Nanotoxicology 9(3), 373-380 (2015).
23. Lin Z, Monteiro-Riviere NA, Riviere JE. A physiologically based pharmacokinetic model for polyethylene glycolcoated gold nanoparticles of different sizes in adult mice. Nanotoxicology doi:10.3109/17435390.2015.1027314 (2015) (Epub ahead of print).
24. Sasidharan A, Monteiro-Riviere NA. Biomedical applications of gold nanomaterials: opportunities and challenges. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7(6), 779-796 (2015).
25. Fent GM, Casteel SW, Kim DY et al. Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine. Nanomedicine 5(2), 128-135 (2009).
26. Balasubramanian SK, Jittiwat J, Manikandan J, Ong CN, Yu LE, Ong WY. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 31(8), 2034-2042 (2010).
27. Morais T, Soares ME, Duarte JA et al. Effect of surface coating on the biodistribution profile of gold nanoparticles in the rat. Eur. J. Pharm. Biopharm. 80(1), 185-193 (2012).
28. Pharmacokinetic model database at the Institute of Computational Comparative Medicine at Kansas State University. http://iccm.k-state.edu/
29. Lin Z, Li M, Gehring R, Riviere JE. Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. J. Pharm. Sci. 104(1), 233-243 (2015).
30. Lin Z, Fisher JW, Wang R, Ross MK, Filipov NM. Estimation of placental and lactational transfer and tissue distribution of atrazine and its main metabolites in rodent dams, fetuses, and neonates with physiologically based pharmacokinetic modeling. Toxicol. Appl. Pharmacol. 273(1), 140-158 (2013).
31. Crowell SR, Henderson WM, Kenneke JF, Fisher JW. Development and application of a physiologically based pharmacokinetic model for triadimefon and its metabolite triadimenol in rats and humans. Toxicol. Lett. 205(2), 154-162 (2011).
32. Upton RN. Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. J. Pharmacol. Toxicol. Methods 58(3), 198-205 (2008).
33. Buur JL, Baynes RE, Craigmill AL, Riviere JE. Development of a physiologic-based pharmacokinetic model for estimating sulfamethazine concentrations in swine and application to prediction of violative residues in edible tissues. Am. J. Vet. Res. 66(10), 1686-1693 (2005).
34. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13(4), 407-484 (1997).
35. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10(7), 1093-1095 (1993).
36. Kattumuri V, Katti K, Bhaskaran S et al. Gum arabic as a phytochemical construct for the stabilization of gold nanoparticles: in vivo pharmacokinetics and x-ray-contrastimaging studies. Small 3(2), 333-341 (2007).
37. Fraga S, Brandao A, Soares ME et al. Short-and longterm distribution and toxicity of gold nanoparticles in the rat after a single-dose intravenous administration. Nanomedicine 10(8), 1757-1766 (2014).
38. International Programme on Chemical Safety Harmonization Project Document No. 9. Characterization and application of physiologically based pharmacokinetic models in risk assessment. World Health Organization, Geneva, Switzerland, 1-91 (2010).
39. Libutti SK, Paciotti GF, Byrnes AA et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 16(24), 6139-6149 (2010). Reports the plasma pharmacokinetics of a gold nanoparticle-based nanomedicine in human cancer patients.
40. Akunda JK, Ahrens FA, Kramer TT. Evaluation of phagocytosis, bactericidal activity, and production of superoxide anion, nitric oxide, and tumor necrosis factoralpha in Kupffer cells of neonatal pigs. Am. J. Vet. Res. 62(7), 1040-1045 (2001).
41. Alabraba EB, Curbishley SM, Lai WK, Wigmore SJ, Adams DH, Afford SC. A new approach to isolation and culture of human Kupffer cells. J. Immunol. Methods 326(1-2), 139-144 (2007).
42. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 52, 481-503 (2012).
43. Mironava T, Hadjiargyrou M, Simon M, Jurukovski V, Rafailovich MH. Gold nanoparticles cellular toxicity and recovery: effect of size, concentration and exposure time. Nanotoxicology 4(1), 120-137 (2010).
44. Love SA, Thompson JW, Haynes CL. Development of screening assays for nanoparticle toxicity assessment in human blood: preliminary studies with charged Au nanoparticles. Nanomedicine (Lond.) 7(9), 1355-1364 (2012).
45. Martin SA, Mclanahan ED, Bushnell PJ, Hunter ES, 3rd, El-Masri H. Species extrapolation of life-stage physiologically-based pharmacokinetic (PBPK) models to investigate the developmental toxicology of ethanol using in vitro to in vivo (IVIVE) methods. Toxicol. Sci. 143(2), 512-535 (2015).
46. Cesta MF. Normal structure, function, and histology of the spleen. Toxicol. Pathol. 34(5), 455-465 (2006).
47. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp. Hepatol. 1(1), 1 (2002).
48. Monteiro-Riviere NA, Banks YB, Birnbaum LS. Laser Doppler measurements of cutaneous blood flow in ageing mice and rats. Toxicol. Lett. 57(3), 329-338 (1991).
49. Mclean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev. 56(2), 163-184 (2004).
50. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5(12), 953-964 (2005).
51. Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano 7(9), 7442-7447 (2013).
52. Kreyling WG, Abdelmonem AM, Ali Z et al. In vivo integrity of polymer-coated gold nanoparticles. Nat. Nanotechnol. 10(7), 619-623 (2015). Demonstrates that gold nanoparticles coated with polymer shells can change their physicochemical properties in vivo due to degradation of the polymer shell by proteolytic enzymes in the liver.